Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.

ABSTRACT: BACKGROUND:Patient-derived xenograft (PDX) models with definite molecular signature are attractive preclinical models for development of novel targeted drugs. Here, we profiled and explored potential therapeutic targets based on characterized PDX models for advanced gastric cancer (AGC). METHODS:The genomic variation and molecular profile of 50 PDX models from AGC patients were analyzed by targeted next-generation sequencing, in situ hybridization, and immunohistochemistry. The antitumor activities of several targeted drugs were investigated in the PDX models. Furthermore, response biomarkers were explored. RESULTS:Each PDX model had individual histopathological and molecular features, and recurrent alterations in the MAPK, ErbB, VEGF, mTOR, and cell cycle signaling pathways were major eve

SUBMITTER: Chen Z 

PROVIDER: S-EPMC5809945 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature